Skip to main content
Top
Published in: Journal of Cancer Survivorship 4/2009

Open Access 01-12-2009

Confronting chemobrain: an in-depth look at survivors’ reports of impact on work, social networks, and health care response

Authors: Nelli Boykoff, Mona Moieni, Saskia Karen Subramanian

Published in: Journal of Cancer Survivorship | Issue 4/2009

Login to get access

Abstract

Introduction

Mild cognitive impairment following chemotherapy is one of the most commonly reported post treatment symptoms by breast cancer survivors. This deterioration in cognitive function, commonly referred to as “chemobrain” or “chemofog,” was largely unacknowledged by the medical community until recent years. Although chemobrain has now become the subject of more vigorous exploration, little is known about this specific phenomenon’s psychosocial impact on breast cancer survivors. This research documents in-depth the effects that cognitive impairment has on women’s personal and professional lives, and our data suggest that greater attention needs to be focused on this arena of survivorship.

Methods

The results are based on an in-depth qualitative study of 74 white and African American breast cancer survivors in California who experience post-treatment side effects. The data reported herein were obtained through the use of focus groups and in-depth interviews.

Results

Our data indicate that cognitive impairment can be problematic for survivors, with many asserting that it is their most troublesome post treatment symptom. Survivors report diminished quality of life and daily functioning as a result of chemobrain. Respondents detail a range of coping strategies that they are forced to employ in order to manage their social and professional lives.

Discussions/conclusions

Chemobrain significantly impairs a proportion of cancer survivors, at great cost to them economically, emotionally, and interpersonally. This suggests that more research needs to be conducted on the psychosocial ramifications of post treatment symptoms in order to inform the efforts of the medical and mental health communities as well as the support networks of survivors.

Implications for cancer survivors

A better and broader understanding of the effects of cognitive impairment both in the medical community and among lay people could pave the way for improved social and psychological services for this population.
Literature
3.
go back to reference Grober SE. Resources for treatment of chemotherapy-related cognitive difficulty. Cancer Pract. 2002;19:216–8.CrossRef Grober SE. Resources for treatment of chemotherapy-related cognitive difficulty. Cancer Pract. 2002;19:216–8.CrossRef
4.
go back to reference Wienke MH, Dienst E. Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psychooncology. 1995;4:61–6.CrossRef Wienke MH, Dienst E. Neuropsychological assessment of cognitive functioning following chemotherapy for breast cancer. Psychooncology. 1995;4:61–6.CrossRef
5.
go back to reference Schagen SB, Van Dam FS, Muller MJ, Boogerd W, Lindeboom J, Bruning PF. Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer. 1999;85:640–50.CrossRefPubMed Schagen SB, Van Dam FS, Muller MJ, Boogerd W, Lindeboom J, Bruning PF. Cognitive deficits after postoperative adjuvant chemotherapy for breast carcinoma. Cancer. 1999;85:640–50.CrossRefPubMed
6.
go back to reference Van Dam FS, Schagen SB, Mueller MJ, Boogerd W, van der Wall E, Droogleever Fortuyen ME, et al. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose vs. standard-dose chemotherapy. J Natl Cancer Inst. 1998;90:182–3.CrossRef Van Dam FS, Schagen SB, Mueller MJ, Boogerd W, van der Wall E, Droogleever Fortuyen ME, et al. Impairment of cognitive function in women receiving adjuvant treatment for high-risk breast cancer: high-dose vs. standard-dose chemotherapy. J Natl Cancer Inst. 1998;90:182–3.CrossRef
7.
go back to reference Brezden CB, Phillips KA, Abdolell M, Bunston T, Tannock IF. Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol. 2000;18:2695–701.PubMed Brezden CB, Phillips KA, Abdolell M, Bunston T, Tannock IF. Cognitive function in breast cancer patients receiving adjuvant chemotherapy. J Clin Oncol. 2000;18:2695–701.PubMed
8.
go back to reference Ahles TA, Saykin AJ, Furstenberg CT, Cole B, Mott LA, Skalla K, et al. Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol. 2002;20:485–93.CrossRefPubMed Ahles TA, Saykin AJ, Furstenberg CT, Cole B, Mott LA, Skalla K, et al. Neuropsychologic impact of standard-dose systemic chemotherapy in long-term survivors of breast cancer and lymphoma. J Clin Oncol. 2002;20:485–93.CrossRefPubMed
9.
go back to reference Castellon SA, Ganz PA, Bower JE, Petersen L, Abraham L, Greendale GA. Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J Clin Exp Neuropsychol. 2004;26:955–69.CrossRefPubMed Castellon SA, Ganz PA, Bower JE, Petersen L, Abraham L, Greendale GA. Neurocognitive performance in breast cancer survivors exposed to adjuvant chemotherapy and tamoxifen. J Clin Exp Neuropsychol. 2004;26:955–69.CrossRefPubMed
10.
go back to reference Shilling V, Jenkins V, Morris R, Deutsch G, Bloomfield D. The effects of adjuvant chemotherapy on cognition in women with breast cancer—preliminary results of an observational longitudinal study. Breast. 2005;14:142–50.CrossRefPubMed Shilling V, Jenkins V, Morris R, Deutsch G, Bloomfield D. The effects of adjuvant chemotherapy on cognition in women with breast cancer—preliminary results of an observational longitudinal study. Breast. 2005;14:142–50.CrossRefPubMed
11.
go back to reference Bender CM, Sereika SM, Berga SL, Vogel VG, Brufsky AM, Paraska KK, et al. Cognitive impairment associated with adjuvant therapy in breast cancer. Psycho-Oncology. 2006;15:422–30.CrossRefPubMed Bender CM, Sereika SM, Berga SL, Vogel VG, Brufsky AM, Paraska KK, et al. Cognitive impairment associated with adjuvant therapy in breast cancer. Psycho-Oncology. 2006;15:422–30.CrossRefPubMed
12.
go back to reference Hurria A, Rosen C, Hudis C, Zuckerman E, Panageas KS, Lachs MS, et al. Cognitive function of older patients receiving adjuvant chemotherapy for breast cancer: a pilot prospective longitudinal study. J Am Geriatr Soc. 2006;54:925–31.CrossRefPubMed Hurria A, Rosen C, Hudis C, Zuckerman E, Panageas KS, Lachs MS, et al. Cognitive function of older patients receiving adjuvant chemotherapy for breast cancer: a pilot prospective longitudinal study. J Am Geriatr Soc. 2006;54:925–31.CrossRefPubMed
13.
go back to reference Raffa RB, Duong PV, Finney J, Garber DA, Lam LM, Matthew SS. Is chemo-fog/chemo-brain caused by cancer chemotherapy? J Clin Pharm Ther. 2006;31:129–38.CrossRefPubMed Raffa RB, Duong PV, Finney J, Garber DA, Lam LM, Matthew SS. Is chemo-fog/chemo-brain caused by cancer chemotherapy? J Clin Pharm Ther. 2006;31:129–38.CrossRefPubMed
14.
go back to reference Silverman DH, Dy CJ, Castellon SA, Lai J, Pio BS, Abraham L, et al. Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5–10 years after chemotherapy. Breast Cancer Res Treat. 2007;103:303–11.CrossRefPubMed Silverman DH, Dy CJ, Castellon SA, Lai J, Pio BS, Abraham L, et al. Altered frontocortical, cerebellar, and basal ganglia activity in adjuvant-treated breast cancer survivors 5–10 years after chemotherapy. Breast Cancer Res Treat. 2007;103:303–11.CrossRefPubMed
15.
go back to reference Nelson CJ, Nandy N, Roth AJ. Chemotherapy and cognitive deficits: mechanisms, findings, and potential interventions. Palliat Support Care. 2007;5:273–80.PubMed Nelson CJ, Nandy N, Roth AJ. Chemotherapy and cognitive deficits: mechanisms, findings, and potential interventions. Palliat Support Care. 2007;5:273–80.PubMed
16.
go back to reference Kannarkat G, Lasher EE, Schiff D. Neurologic complications of chemotherapy agents. Curr Opin Neurol. 2007;20:719–25.PubMed Kannarkat G, Lasher EE, Schiff D. Neurologic complications of chemotherapy agents. Curr Opin Neurol. 2007;20:719–25.PubMed
17.
go back to reference Tangpong J, Cole MP, Rukhsana S, Estus S, Vore M, St. Clair W, et al. Adriamycin-mediated nitration of manganese superoxide dismutase in the central nervous system: insight into the mechanism of chemobrain. J Neurochem. 2007;100:191–201.CrossRefPubMed Tangpong J, Cole MP, Rukhsana S, Estus S, Vore M, St. Clair W, et al. Adriamycin-mediated nitration of manganese superoxide dismutase in the central nervous system: insight into the mechanism of chemobrain. J Neurochem. 2007;100:191–201.CrossRefPubMed
18.
19.
go back to reference Wefel J, Lenzi R, Theriault R, Buzdar A, Cruickshank MC. ‘Chemobrain’ in breast carcinoma? A prologue. Cancer. 2004;101:466–75.CrossRefPubMed Wefel J, Lenzi R, Theriault R, Buzdar A, Cruickshank MC. ‘Chemobrain’ in breast carcinoma? A prologue. Cancer. 2004;101:466–75.CrossRefPubMed
20.
go back to reference Donovan K, Small B, Andrykowski M, Schmitt F, Munster P, Jacobsen P. Cognitive functioning after adjuvant chemotherapy and /or radiotherapy for early-stage breast carcinoma. Cancer. 2005;104:2499–507.CrossRefPubMed Donovan K, Small B, Andrykowski M, Schmitt F, Munster P, Jacobsen P. Cognitive functioning after adjuvant chemotherapy and /or radiotherapy for early-stage breast carcinoma. Cancer. 2005;104:2499–507.CrossRefPubMed
21.
go back to reference Jenkins V, Shilling V, Deutsch G, Bloomfield D, Morris R, et al. A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. Br J Cancer. 2006;94:828–34.CrossRefPubMed Jenkins V, Shilling V, Deutsch G, Bloomfield D, Morris R, et al. A 3-year prospective study of the effects of adjuvant treatments on cognition in women with early stage breast cancer. Br J Cancer. 2006;94:828–34.CrossRefPubMed
22.
go back to reference Shilling V, Jenkins V. Self-reported cognitive problems in women receiving adjuvant therapy for breast cancer. Eur J Oncol Nursing. 2007;11:6–15.CrossRef Shilling V, Jenkins V. Self-reported cognitive problems in women receiving adjuvant therapy for breast cancer. Eur J Oncol Nursing. 2007;11:6–15.CrossRef
23.
24.
go back to reference Falleti MG, Sanfilippo A, Maruff P, Weih L, Phillips KA. The nature and severity of cognitive impairment associated with adjuvant chemotherapy in women with breast cancer: a meta-analysis of the current literature. Brain Cogn. 2005;59:60–70.CrossRefPubMed Falleti MG, Sanfilippo A, Maruff P, Weih L, Phillips KA. The nature and severity of cognitive impairment associated with adjuvant chemotherapy in women with breast cancer: a meta-analysis of the current literature. Brain Cogn. 2005;59:60–70.CrossRefPubMed
25.
go back to reference Matsuda T, Takayama T, Tashiro M, Nakamura Y, Ohashi Y, Shimozuma K. Mild cognitive impairment after adjuvant chemotherapy in breast cancer patients—evaluation of appropriate research design and methodology to measure symptoms. Breast Cancer. 2005;12:279–87.CrossRefPubMed Matsuda T, Takayama T, Tashiro M, Nakamura Y, Ohashi Y, Shimozuma K. Mild cognitive impairment after adjuvant chemotherapy in breast cancer patients—evaluation of appropriate research design and methodology to measure symptoms. Breast Cancer. 2005;12:279–87.CrossRefPubMed
26.
go back to reference Bender CM, Paraska KK, Sereika SM, Ryan CM, Berga SL. Cognitive function and reproductive hormones in adjuvant therapy for breast cancer: a critical review. J Pain Symptom Manage. 2001;21:407–24.CrossRefPubMed Bender CM, Paraska KK, Sereika SM, Ryan CM, Berga SL. Cognitive function and reproductive hormones in adjuvant therapy for breast cancer: a critical review. J Pain Symptom Manage. 2001;21:407–24.CrossRefPubMed
27.
go back to reference Gross J. Chemotherapy is no longer ignored as illusion. The New York Times; 29 Apr 2007. Gross J. Chemotherapy is no longer ignored as illusion. The New York Times; 29 Apr 2007.
28.
go back to reference Hoag H. The foggy world of chemobrain. The Toronto Star; 3 Nov 2007. Hoag H. The foggy world of chemobrain. The Toronto Star; 3 Nov 2007.
29.
go back to reference Breast cancer: new software program helps breast cancer survivors and patients fight chemofog. Drug Week; 19 Oct 2007. Breast cancer: new software program helps breast cancer survivors and patients fight chemofog. Drug Week; 19 Oct 2007.
30.
go back to reference Fitch MI, Armstrong J, Tsang S. Patients’ experiences with cognitive changes after chemotherapy. Can Oncol Nurs J. 2008;18(4):180–92.PubMed Fitch MI, Armstrong J, Tsang S. Patients’ experiences with cognitive changes after chemotherapy. Can Oncol Nurs J. 2008;18(4):180–92.PubMed
31.
go back to reference Downie FP, Mar Fan HG, Houédé-Tchen N, Yi Q, Tannock IF. Cognitive function, fatigue, and menopausal symptoms in breast cancer patients receiving adjuvant chemotherapy: evaluation with patient interview after formal assessment. Psychooncology. 2006;15(10):921–30.CrossRefPubMed Downie FP, Mar Fan HG, Houédé-Tchen N, Yi Q, Tannock IF. Cognitive function, fatigue, and menopausal symptoms in breast cancer patients receiving adjuvant chemotherapy: evaluation with patient interview after formal assessment. Psychooncology. 2006;15(10):921–30.CrossRefPubMed
32.
go back to reference Crabtree BF, Miller WL. Doing qualitative research. Sage: Newbury Park; 1992. Crabtree BF, Miller WL. Doing qualitative research. Sage: Newbury Park; 1992.
Metadata
Title
Confronting chemobrain: an in-depth look at survivors’ reports of impact on work, social networks, and health care response
Authors
Nelli Boykoff
Mona Moieni
Saskia Karen Subramanian
Publication date
01-12-2009
Publisher
Springer US
Published in
Journal of Cancer Survivorship / Issue 4/2009
Print ISSN: 1932-2259
Electronic ISSN: 1932-2267
DOI
https://doi.org/10.1007/s11764-009-0098-x

Other articles of this Issue 4/2009

Journal of Cancer Survivorship 4/2009 Go to the issue
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine